Oriola Oyj (ORIOLA) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Oriola Oyj stock €0.72, price €0.79, that is 8.3% below the price, quality 52 out of 100. Rating: fairly valued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range €0.7390 – €1.84 · fair‑value band €0.7100 – €0.7200 · the €0.7850 price screens above the €0.7200 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Oriola in your weekly email
Every Wednesday you see whether Oriola is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Oriola Oyj engages in the wholesale of pharmaceuticals and health products in Sweden, Finland, and internationally. The company distributes vitamins, food and food supplements, sports nutrients, wound care, beauty, and makeup related products; vaccines; and over-the-counter products.
Show moreShow less
In addition, it provides pharmaceutical logistics; special licensed medicine importing, dose dispensing, and research pharmacy services; and commercial data, clinical trial, regulatory affairs and quality, medical and scientific affairs, market access and tenders, real world evidence, sales support, medical translation, pharmacovigilance and medical information, and patient support services.
Further, the company provides advisory services. It serves pharmaceutical companies, pharmacies, veterinarians, hospitals, healthcare providers, special stores, retailers, and e-commerce companies. The company was founded in 1907 and is headquartered in Espoo, Finland.
Stock analysis
Oriola Oyj (ORIOLA) currently trades at €0.7850, while our model-based Fair Value estimate is €0.7200, so the stock looks roughly fairly valued today (gap 9.0%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of €3.23 per share, and 8 of the 13 models we run sit above the €0.7850 price.
Bear case: the Asset-Based group reads lowest at €0.2100, and 5 of the 13 models stay below the price. Data coverage for this calculation is low.
Scenario range: €0.7100 (bear) to €0.7200 (bull), the price of €0.7850 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Oriola Oyj reported revenue of €1.9B in FY2025 versus €1.5B in FY2021, a compound +7.0%/yr. Reported net income was −€27.2M in FY2025.
Key figures
Market cap €145M Micro · P/S ratio 0.08 · EPS (TTM) €−0.1100 · Dividend yield 3.8% · Net margin −1.0% · Return on equity −18.3% · Return on assets (EBIT) 3.3% (5-year average) · Operating margin 5.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 20 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside, at −8%, ORIOLA screens richer than that median.
Fair Value models
Bear€0.7100Fair Value €0.7200Bull€0.7200
Price €0.7850 · Downside -8.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.31/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+13.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.1%
Start year 2020 (pandemic). Over 10 years: +1.6% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
1.9% (2020) → 0.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
The company could shrink this much every year for the next five years and today's price would still be justified.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 50 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside−8.3% · Below median
Profitability
Return on assets−2.9% · Bottom 25%
Net margin (12 months)−1.0% · Bottom 25%
Operating margin (12 months)5.7% · Above median
Growth and dividend
Revenue growth (quarter YoY)5.2% · Above median
Dividend yield (12 months)3.8% · Above median
Balance sheet
Debt / equity0.30× · Above median
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Oriola Oyj Fair Value". https://www.fairvalue-calculator.com/stock/ORIOLA
Frequently asked questions
Is Oriola Oyj (ORIOLA) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of €0.7200 versus a price of €0.7850, about 8% lower (fairly valued).
What is the fair value of ORIOLA?
Our model-based fair value for Oriola Oyj is €0.7200 (as of Nov 4, 2026), built from audited fundamentals. The current price: €0.7850.
What is the quality score of ORIOLA?
Oriola Oyj has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oriola Oyj (ORIOLA)?
Our model-based price target is the fair value of €0.7200 (as of Nov 4, 2026) from 13 valuation models. Cautious scenario €0.7100, optimistic scenario €0.7200. It is a calculation from audited fundamentals, not an analyst target.
What is the Oriola Oyj stock forecast for 2026?
Our models put fair value at €0.7200, about 8% lower versus a price of €0.7850 (fairly valued). Cautious scenario €0.7100, optimistic scenario €0.7200. The calculation is refreshed regularly with new filings.
What is the revenue of Oriola Oyj (ORIOLA)?
Oriola Oyj reported trailing-twelve-month revenue of about €1.9B (latest available figure, as of Nov 4, 2026).
Does Oriola Oyj pay a dividend?
Oriola Oyj currently shows a dividend yield of 3.82% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of Oriola Oyj (ORIOLA) and when is the ex-dividend date?
Oriola Oyj pays a dividend of €0.03 per share a year, a dividend yield of 3.8%. The last ex-dividend date was Mar 26, 2026. A dividend has been paid every year since 2016. Free cash flow covers the dividend 10.26 times. Our assessment: Cash covered. The dividend is fully funded by free cash flow. The payout ratio on earnings is not available for this company.
What growth is priced into Oriola Oyj (ORIOLA)?
For today's price to be fair in a discounted-cash-flow model, Oriola Oyj would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 11.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +1.1 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of ORIOLA use?
Our models discount Oriola Oyj at 11.4 %: a base by market capitalisation (micro), damped by beta 0.46, country premium for Finland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Oriola Oyj that is less than minus 40 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.4 %) and the same formula as our fair value.
How much growth has Oriola Oyj (ORIOLA) delivered so far?
Over the past 5 years revenue at Oriola Oyj grew +1.1 % a year. The price currently implies free-cash-flow growth of less than minus 40 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Oriola Oyj (ORIOLA) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Oriola Oyj (less than minus 40 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Oriola Oyj (ORIOLA)?
The free-cash-flow yield on the price is 39.03 %: that much free cash flow Oriola Oyj produces per unit of market value. When it exceeds the discount rate of our models (11.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Oriola Oyj (ORIOLA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oriola Oyj it is €0.7200 per share (as of Nov 4, 2026), against a price of €0.7850. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Oriola Oyj stock overvalued or undervalued in 2026?
As of Nov 4, 2026, ORIOLA trades above its calculated fair value: price €0.7850, fair value €0.7200, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ORIOLA?
No. The price is what the market pays today (€0.7850); the fair value is what the company's own numbers justify (€0.7200). For Oriola Oyj the two are €0.0650 per share apart. That gap is exactly why we show both numbers side by side.
How much is Oriola Oyj worth?
The market values Oriola Oyj at about €145M (market capitalisation, as of Nov 4, 2026). Per share that is €0.7850; our models calculate a fair value of €0.7200 per share.
What do the bullish and bearish scenarios say about ORIOLA?
Our models span a range for Oriola Oyj: cautious scenario €0.7100, base €0.7200, optimistic €0.7200 per share (as of Nov 4, 2026, price €0.7850). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of ORIOLA?
The PEG ratio of Oriola Oyj is 13.54 (P/E divided by earnings growth, as of Nov 4, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Oriola Oyj (ORIOLA)?
Balance-sheet figures for Oriola Oyj (as of Nov 4, 2026): return on equity −18.3%, debt of 0.30 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is ORIOLA from its 52-week high?
Oriola Oyj trades at €0.7850, about 35% below its 52-week high of €1.22 and 6% above the low of €0.7390 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €0.7200 is for.
Which stocks are comparable to Oriola Oyj?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oriola Oyj stock attractive at the current price?
The data as of Nov 4, 2026: price €0.7850, calculated fair value €0.7200 (−8%), Quality Score 52/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ORIOLA calculated?
We run Oriola Oyj through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of €0.7200 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Oriola Oyj itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oriola Oyj (ORIOLA)?
The closing price on Nov 6, 2026 was €0.7850. Our model-based fair value is €0.7200, about 8% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oriola Oyj right now?
The price sits above even our optimistic bull case (€0.7200). The favourable scenario is already priced in. The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (€0.7100 to €0.7200), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Oriola Oyj
How large is the market capitalisation of Oriola Oyj (ORIOLA)?
The market capitalisation of Oriola Oyj is €145M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Oriola Oyj (ORIOLA)?
The price-to-sales ratio of Oriola Oyj is 0.08 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Oriola Oyj (ORIOLA)?
Earnings per share at Oriola Oyj are €−0.1100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Oriola Oyj (ORIOLA)?
The dividend yield of Oriola Oyj is 3.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Oriola Oyj (ORIOLA)?
The net margin of Oriola Oyj is −1.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Oriola Oyj (ORIOLA)?
The return on equity (ROE) of Oriola Oyj is −18.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oriola Oyj (ORIOLA)?
On an EBIT basis the return on assets of Oriola Oyj is 3.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oriola Oyj (ORIOLA)?
The operating margin of Oriola Oyj is 5.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oriola Oyj (ORIOLA)?
Revenue at Oriola Oyj is growing +5.2% versus a year earlier (3y avg +7.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Oriola Oyj (ORIOLA)?
Earnings per share at Oriola Oyj are growing +9.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Oriola Oyj (ORIOLA) hold?
Oriola Oyj holds more cash than debt, €73.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Oriola Oyj in the live analysis
One click puts Oriola Oyj on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026